
Opinion|Videos|October 14, 2024
Exploring the Kidney-CHAMP Study
Key Takeaways
- The trial focused on improving cardiovascular risk management in type 2 diabetes through a coordinated care model involving healthcare systems.
- Interventions included educational sessions, feedback, and support for healthcare providers to enhance adherence to guideline-directed medical therapy.
A panel of experts explores the objectives and design of the COORDINATE-Diabetes trial, discussing its potential impact on the treatment paradigm for diabetes management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Tell us about Kidney-CHAMP study.
- What were the objectives of Kidney-CHAMP and how was the study designed?
- What interventions were provided?
- What were the results of the study?
- What are future opportunities to improve CRM care based on this study?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives
2
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
3
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
4
Complicated UTI Care Strained by Unclear Goals, Access Gaps
5

